Regeneron Bolsters I-O Portfolio with US$250 M Checkmate Acquisition
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 4 (Table of Contents)
Published: 21 Apr-2022
DOI: 10.3833/pdr.v2022.i4.2686 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In an attempt to expand its immuno-oncology portfolio, Regeneron has agreed to acquire Checkmate Pharmaceuticals for US$10...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018